Edwards Lifesciences

    Heart disease causes one in four American deaths every year. Edwards Lifesciences, which creates artificial heart valves, including for patients deemed too risky for open surgery, has significantly expanded its international footprint and shows no signs of slowing down. The most promising growth avenue is among lower-risk patients who require noninvasive heart valve replacements.

    Subscribe to Fortune’s Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.

    Company Information

    Overall Score1.6
    SectorHealth Care
    IndustryHealth Care Equipment and Supplies
    CEOMichael Mussallem
    HQ LocationIrvine, Calif.
    Revenues ($M) (Past 12 Months)$3,964
    Profits ($M) (Past 12 Months)$725
    Market Value as of Oct. 9, 2019 ($M)$46,754